巴林使用开创性的 CRISPR 疗法 Casgevy 治疗首例国际镰状细胞患者。 Bahrain treats first international sickle cell patient with pioneering CRISPR therapy, Casgevy.

巴林已成为美国以外第一个成功使用CRISPR基因编辑疗法治疗状细胞病患者的国家, Bahrain has become the first country outside the U.S. to successfully treat a sickle cell disease patient using CRISPR gene-editing therapy called Casgevy. Casgevy是首次使用CRISPR/Cas9技术获得执照的治疗,为镰状细胞疾病提供了可能的功能治疗。 Developed by Vertex Pharmaceuticals and CRISPR Therapeutics, Casgevy is the first licensed therapy using CRISPR/Cas9 technology, offering a potential functional cure for sickle cell disease. 这一成就与巴林推进保健创新和全球伙伴关系的战略相一致。 This achievement aligns with Bahrain's strategy to advance healthcare innovation and global partnerships.